POST-PROGRESSION AND SAFETY OUTCOMES WITH FIRST-LINE (1L) AMIVANTAMAB PLUS LAZERTINIB VERSUS OSIMERTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH COMMON EGFR MUTATIONS: IMPLICATIONS FOR BEST MANAGEMENT PRACTICES
ONCOLOGY NURSING FORUM（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined